Worth reading
22Immaterial
Scored from 2 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Impact on Business Performance
The impact of this matter on the Company's financial results is minor.
| Item | Details |
|---|---|
| Impact on Business Performance | The impact of this matter on the Company's financial results is minor. |
Items this document does not state (22)
Name of alliance partnerAlliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because limited clinical research was conducted and progress was made in clinical trials concerning the efficacy of fucoxanthinol.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.